c-Met is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
| Property | Value | Notes |
|---|---|---|
| Primary reported target | Hepatocyte growth factor/c-Met signaling | Findings mainly from cell and animal studies. |
| Related endogenous peptide | Angiotensin IV | Dihexa is described as a stabilized analog. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for purity assessment. |
| Identity confirmation | Mass spectrometry | Provides a molecular mass check. |
| Regulatory status | Not approved for human use | Sold as a research chemical in many jurisdictions. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
== Gene == The gene encoding this enzyme has been identified by Jakub Drozak and coworkers in 2010. The gene encoding the Carnosine synthase is ATPGD1, a member of the “ATP-grasp family” of ligases. Because of its involvement in the formation of carnosine, this gene is now also named 'CARNS1'.
== Medical uses == Amitriptyline/chlordiazepoxide is used for the treatment of moderate to severe depression associated with moderate to severe anxiety. It has shown to be more effective in treating symptoms of anxiety, irritability, and hostility in patients with comorbid depression and anxiety than amitriptyline alone. It also has a quicker onset time than either amitriptyline or chlordiazepoxide on their own.
=== Resilience === Another unique property of resilin is its high resilience. Recombinant resilin demonstrated excellent mechanical properties similar to that of pure resilin. Elvin et al. aimed to compare the resilience of rec1-Resilin to other rubbers, a scanning probe microscope of used. This study compared the resilience of rec1-Resilin to two different types of rubber: chlorobutyl rubber and polybutadiene rubber, both rubbers with high resilience properties. This study concluded that rec1-Resilin was 92% resilient compared to chlorobutyl rubber at 56% and polybutadiene rubber at 80%, respectively. With such high mechanical resilience, the properties of rec1-Resilin can be applied to other clinical applications within the field of Materials Engineering and Medicine. This study on recombinant resilin has led to several years of research on the use of resilin like proteins for several biomedical applications that retains the mechanical properties of resilin. The ongoing results of the studies involving recombinant resilin may lead to further research in which other unexplored mechanical properties and chemical structure of resilin may be investigated.
==== Stress and addiction ==== Stress contributes to both the development and the persistence of addiction, affecting neurophysiological pathways, decision-making and relapse risk. Acute and chronic stress activate the hypothalamic–pituitary–adrenal axis, raising levels of cortisol and corticotropin-releasing hormone; these changes alter reward processing and increase the motivational pull of substances, particularly those that temporarily relieve negative mood. In animal studies, repeated stress exposure increases dopamine release in the nucleus accumbens and sensitizes the mesolimbic reward system, making drugs more reinforcing. Chronic stress also disturbs glutamatergic signaling in the prefrontal cortex, impairing inhibitory control and self-regulation, which increases susceptibility to compulsive drug seeking and reduces the ability to disregard drug-associated cues. Stress is among the more reliable predictors of relapse. In human neuroimaging studies, stress-induced activation of the amygdala together with reduced prefrontal regulation is associated with self-reported craving and with subsequent return to use. People with a history of trauma, or of chronic social stress such as discrimination, poverty or housing insecurity, are at increased risk of substance use disorders. Because stress interacts with reward circuitry and decision-making systems, many treatment approaches incorporate stress-reduction strategies, including cognitive behavioral therapy, mindfulness-based interventions and medications acting on stress-related neurochemistry.
The metabolism of thiotepa primarily takes place in the liver, following both phase 1 and phase 2 metabolic pathways. Phase 1 involves reactions which change chemical moieties such as oxidation, reduction, and hydrolysis, while phase 2 includes the addition of endogenous groups to foreign compounds. Phase 1 metabolism of thiotepa is predominantly mediated by the cytochrome P450 enzyme system, major CYP2B6 and minor CYP3A4. In this phase an oxidation and desulfuration reactions convert thiotepa into its more active metabolite tepa. Tepa itself exhibits a longer plasma half-life (3 to 24 hours) than thiotepa (1 to 3 hours) and contributes to the overall pharmacological activity of the drug. In phase 2 thiotepa is detoxified via the conjugation with glutathione by glutathione S-transferase. This is followed by the removal of the glutamyl and glycine moieties, and concludes with the N-acetylation of the cysteine conjugate by N-acetylase to form thiotepa-mercapturate. This derivative is more water-soluble, facilitating urinary excretion. Tepa is not conjugated to glutathione but reacts further in the urine and plasma to monochloro tepa. The conversion to a β-chloroethyl moiety depends on the pH and the chloride concentration. The formation of monochloride tepa mainly occurs in the urine. Enzymes responsible for metabolising compounds can show varying efficiency in different individuals or populations, this is called polymorphism. In a study regarding thiotepa metabolism by Ekhart et al., it was found that glutathione S-transferase shows polymorphism.
Sources: en.wikipedia.org
== International reactions == Canada: Canada's ambassador to the United Nations compared U.S. president Donald Trump's Golden Dome to a protection racket after Trump said America's northern neighbor must either pay $61 billion to join the program or could agree to annexation (in which case inclusion would be free). Ambassador Bob Rae also noted that "threats to sovereign integrity are prohibited" under the Charter of the United Nations. Earlier, Canadian minister of national defence Bill Blair had expressed a willingness for participation in the Golden Dome project. China: On 21 May 2025, Foreign Ministry spokesperson Mao Ning criticized the Golden Dome plan, claiming it "violates the principle of peaceful use of space in the Outer Space Treaty". She called on the US to "give up developing and deploying [a] global anti-missile system", which risked "turning space into a war zone". In a white paper published by the State Council Information Office in November 2025, China criticized the move towards "absolute security" and that it would "pose a serious threat to outer space security". New Zealand: New Zealand defence minister Judith Collins expressed support for the Golden Dome missile system, saying "I don't see it as an attack mechanism. It's a defence mechanism. And if people did not feel they needed to defend themselves, they wouldn't waste the money on it." Trump had earlier noted the space-based system would be "a very big part of our defense and, obviously, of our offense" and capable of striking foreign assets even before they launch.
== Other uses == BrightBus, a former British vehicle body manufacturer and school bus operator that previously traded as MASS Engineering Manab Adhikar Sangram Samiti, a human rights NGO in Assam (India) Marc and Eva Stern Math and Science School (Stern MASS) Maritime Autonomous Surface Ship, An autonomous cargo ship Maß (pronounced "mass"), a German word describing the amount of beer in a regulation mug, also used for the mug itself Mass (mass spectrometry), a chemical analysis technique Mass (object), a high-density object Mawson Analytical Spectrometry Services, services offered at the University of Adelaide, Australia Tumor, or mass, a neoplasm that is enlarged
=== Systemic use === Prednisolone is a corticosteroid drug with predominant glucocorticoid and low mineralocorticoid activity, making it useful for the treatment of a wide range of inflammatory and autoimmune conditions such as asthma, uveitis, pyoderma gangrenosum, rheumatoid arthritis, urticaria, angioedema, ulcerative colitis, pericarditis, temporal arteritis, Crohn's disease, Bell's palsy, multiple sclerosis, cluster headaches, vasculitis, acute lymphoblastic leukemia, autoimmune hepatitis, lupus, Kawasaki disease, dermatomyositis, post-myocardial infarction syndrome, and sarcoidosis. Prednisolone can also be used for allergic reactions ranging from seasonal allergies to drug allergic reactions. Prednisolone can also be used as an immunosuppressant for organ transplants. Prednisolone in lower doses can be used in cases of adrenal insufficiency due to Addison's disease.
16 November – In a statement to the Scottish Parliament, Health Secretary Michael Matheson admits the cause of his £11,000 roaming charges bill came from his sons watching football on his parliamentary iPad while the family was on holiday in Morocco. Matheson confirms he has repaid the money and referred himself to the parliamentary watchdog. 17 November – A number of motorists have had their Glasgow Low Emission Zone fines cancelled after a tribunal ruled they were unenforceable due to a "procedural error" made by Glasgow City Council. The Scottish Government publishes its plans for European Union membership in an independent Scotland. 22 November – Petroineos announces to repurpose Grangemouth oil refinery, Scotland's only oil refinery, as a fuels import terminal with the loss of 400 jobs. The McDonald's fast food outlet in Fort William says it has had to ban under 18s from the premises after 6.00pm because of verbal abuse targeted at its staff. 23 November – The Scottish Parliament Corporate Body confirms it has launched an investigation into Health Secretary Michael Matheson's £11,000 data roaming bill. 24 November – Former First Minister Alex Salmond launches a fresh legal case against the Scottish Government over its mishandling of harassment allegations against him. Universities Scotland adopts a new policy that requires potential students offered a place at a university in Scotland to declare any charges for violent offences. 25 November – A police officer is taken to hospital after a civil disturbance breaks out in the East Ayrshire village of Auchinleck.
== Properties == Silica gel's high specific surface area—around 750–800 m2/g (230,000–240,000 sq ft/oz)—allows it to absorb water readily, making it useful as a desiccant (drying agent). Silica gel is often described as "absorbing" moisture, which may be appropriate when the gel's microscopic structure is ignored, as in silica gel packs or other products. However, material silica gel removes moisture by adsorption onto the surface of its numerous pores rather than by absorption into the bulk of the gel. Silica gel is able to absorb up to 37% of its own weight in moisture in high-humidity environments. This moisture can be released upon heating at about 120 °C (248 °F) for 1–2 hours. This makes it reusable multiple times with very little, if any, loss of efficiency.
Sources: en.wikipedia.org
The acute and chronic inflammatory processes of osteoradionecrosis are prevented by the administration of steroidal anti-inflammatory drugs. In addition, the administration of pentoxifylline and antioxidant treatments, such as superoxide dismutase and tocopherol (vitamin E) are recommended.
== Life == Roderich Süssmuth studied chemistry and biochemistry at the Eberhard Karls University of Tübingen from 1990 to 1996. In 1999, he received his doctorate under Günther Jung in Tübingen with a dissertation entitled Isolation, structural elucidation, and synthesis of microbial metabolites from Amycolatopsis mediterranei, Staphylococcus epidermidis, and Streptomyces lividans. During a postdoctoral stay at the Scripps Research Institute in La Jolla, California, United States, from 2000 to 2001, he worked with Richard A. Lerner and Carlos F. Barbas on catalytic antibodies and organocatalysis. As an Emmy Noether Research Fellow (DFG) from 2001 to 2004, he completed his habilitation in chemistry and biochemistry at the University of Tübingen. In 2004, he was appointed Associate Professor of Biological Chemistry at TU Berlin. In 2008, he was appointed to the Rudolf Wiechert Professorship of Biological Chemistry at TU Berlin. In 2020, he was named a Fellow of the Royal Society of Chemistry (FRSC) and an honorary member of the Israel Chemical Society. In 2022, he was admitted to the Confraternity of Santa Maria dell'Anima in Rome.
===== Opioids ===== In humans addicted to opioids, epigenetic modifications of the OPRK1 gene, including altered DNA methylation profiles in peripheral blood cells, correlate with substance use severity and withdrawal symptoms.
=== Legal status === In July 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Nexviadyme, intended for the treatment of glycogen storage disease type II (Pompe disease). The applicant for this medicinal product is Genzyme Europe BV. In August 2021, Genzyme Europe BV requested a re-examination. Avalglucosidase alfa was approved for medical use in the European Union in June 2022. The U.S. Food and Drug Administration (FDA) granted the application for avalglucosidase alfa fast track, priority review, breakthrough therapy, and orphan drug designations. The FDA granted the approval of Nexviazyme to Genzyme Corporation.
Sources: en.wikipedia.org
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.
Reverse-phase high-performance liquid chromatography is commonly used to assess purity. Mass spectrometry is used to confirm molecular identity. These methods are typical for synthetic peptides and research chemicals.
Dihexa is not approved as a drug in major jurisdictions. It is often sold as a research chemical, which is not the same as a medicine. Its legal status can vary by country and may change.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.